Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Focal Laser
Drug · Procedure
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Laser photocoagulation
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional

Topcon Endpoint Management

NCT01732614
Conditions
Diabetic Macular Edema
Interventions
Topcon Endpoint Management laser
Procedure
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Conditions
Diabetic Macular Edema (DME)
Interventions
AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 2 Interventional

Evaluation of Tonabersat for DME

NCT05727891
Conditions
Diabetic Macular Edema
Interventions
Tonabersat, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Huntington Beach, California • Loma Linda, California • Oakland, California + 23 more
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Conditions
Macular Edema
Interventions
dexamethasone Intravitreal Implant, ranibizumab
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Arlington, Texas
Conditions
Diffuse Diabetic Macular Edema
Interventions
iCo-007 Intravitreal Injection
Drug
Lead sponsor
iCo Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Durham, North Carolina + 1 more
Conditions
Diabetic Retinopathy
Interventions
Aflibercept, Sham
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
Drug · Behavioral · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
56
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 46 more
Conditions
Diabetic Macular Edema
Interventions
Laser Photocoagulation, Intravitreal Aflibercept Injection
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetic Macular Edema (DME)
Interventions
ILUVIEN 0.19 MG
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 36 more
Conditions
Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease, Uveitis, Posterior
Interventions
DEX PS DDS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Sunnyvale, California
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more